TY - JOUR
T1 - Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction
T2 - ATLANTIC-Morphine
AU - Lapostolle, Frederic
AU - van't Hof, Arnoud W.
AU - Hamm, Christian W.
AU - Stibbe, Olivier
AU - Ecollan, Patrick
AU - Collet, Jean-Philippe
AU - Silvain, Johanne
AU - Lassen, Jens Flensted
AU - Heutz, Wim M. J. M.
AU - Bolognese, Leonardo
AU - Cantor, Warren J.
AU - Cequier, Angel
AU - Chettibi, Mohamed
AU - Goodman, Shaun G.
AU - Hammett, Christopher
AU - Huber, Kurt
AU - Janzon, Magnus
AU - Merkely, Bela
AU - Storey, Robert F.
AU - ten Berg, Jur
AU - Zeymer, Uwe
AU - Licour, Muriel
AU - Tsatsaris, Anne
AU - Montalescot, Gilles
AU - Bougherbal, Rachid
AU - Bouafia, Mohamed Tahar
AU - Chettibi, Mohamed
AU - Nibouche, Djamaleddine
AU - Moklati, Abdelkader
AU - Benalia, Ahmed
AU - Krim, Messaad
AU - Hammett, Christopher
AU - Garraby, Paul
AU - Jayasinghe, Rohan
AU - Rashford, Stephen
AU - Huber, Kurt
AU - Neunteufl, Thomas
AU - Brussee, Helmut
AU - Alber, Hannes
AU - Weidinger, Franz
AU - Baubin, Michael
AU - Sebald, Dieter
AU - Cantor, Warren
AU - Vijayaraghavan, Ram
AU - Bata, Iqbal
AU - Lavoie, Andrea
AU - Lassen, Jens Flensted
AU - Ravkilde, Jan
AU - Jensen, Lisette Okkels
AU - Christensen, Alf Mol
AU - ATLANTIC Investigators
N1 - Funding Information:
had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The authors would like to thank Richard Cairns, from Worldwide Clinical Trials UK, for statistical analysis. Editorial support was provided by Liz Anfield, Prime, Knutsford, Cheshire, funded by AstraZeneca. All persons named in the acknowledgements section have provided the corresponding author with written permission to be named in the article. ATLANTIC study investigators Algeria: Rachid Bougherbal (Algiers), Mohamed Tahar Boua-fia (Algiers), Mohamed Chettibi (Algiers), Djamaleddine Nibouche (Medea), Abdelkader Moklati (Tipaza), Ahmed Benalia (Algiers), Omar Kaid (Blida), Messaad Krim (Blida).
Funding Information:
Funding This work was supported by AstraZeneca and led by the ACTION Group (Allies in Cardiovascular Trials Initiatives and Organized Networks), www.action-coeur.org.
Funding Information:
Conflict of interest All authors have completed the International Committee of Medical Journal Editors (ICMJE) Form for Disclosure of Potential Conflicts of Interest. Frédéric Lapostolle has received research grants, consultancy fees and honoraria from AstraZeneca, Merck-Serono, Roche, Boehringer-Ingelheim, Bayer, The Medicines Company, Correvio, Daiichi-Sankyo, and Eli-Lilly. Arnoud W. van ‘t Hof has received research grants, consultancy fees and honoraria from AstraZeneca, Medtronic, Daiichi-Sankyo, and Iroko Cardio. Christian W. Hamm has received research grants, consultancy fees, and honoraria from AstraZeneca, Daiichi-Sankyo, Lilly, Sanofi-Aventis, and Boehringer-Ingelheim. Patrick Ecollan has received consultancy fees from AstraZeneca, Abbott Vascular, Eli-Lilly, Sanofi-Aventis, and Biomérieux. Jean-Philippe Collet has received research grants from Bristol-Myers Squibb; consulting fees from Bristol-Myers Squibb, Eli Lilly, and Sanofi-Aventis; and lecture fees from Bristol-Myers Squibb and Sanofi-Aventis. Johanne Silvain has received research grants from Fédération Française de Cardiologie and Société Française de Cardi-ologie; consultancy fees and honoraria from Amgen, Algorythm As-traZeneca, Bayer, Gilead Science and Sanofi-Aventis; and travel support from Amgen, AstraZeneca, Bayer and Bristol-Myers Squibb. Jens Flensted Lassen has received honoraria from AstraZeneca. Leonardo Bolognese has received consultancy fees and honoraria from Astra-Zeneca, Daiichi-Sankyo, Eli-Lilly, Menarini Ind Farma, and Abbott. Warren J. Cantor has received honoraria from AstraZeneca. Mohamed Chettibi has received support from AstraZeneca (study investigator). Shaun G. Goodman has received support from AstraZeneca Canada (National [Canada] Coordinator) and consultancy fees and honoraria from AstraZeneca, Eli-Lilly, and Sanofi. Christopher J. Hammett has received research grants from AstraZeneca and consultancy fees and honoraria from AstraZeneca, Eli-Lilly, Bayer Healthcare, Boehringer-Ingelheim, Amgen, and The Medicines Company. Magnus Janzon has received support from AstraZeneca (National Coordinating Investigator) and Pfizer. Robert Storey has received research grants, consultancy fees and honoraria from AstraZeneca; research grants and consultancy fees from PlaqueTec; consultancy fees from Actelion/Idorsia, Avacta, Bayer, Bristol-Myers Squibb, Pfizer, Novartis, and The Medicines Company. Jur ten Berg has received research grants, consultancy fees and honoraria from AstraZeneca. Uwe Zeymer has received research grants from Daiichi-Sankyo, Eli-Lilly, Novartis and Sanofi and consultancy fees and honoraria from AstraZeneca, Bayer Healthcare, The Medicines Company, Daiichi-Sankyo, Eli-Lilly, Novartis, Sanofi, Boehringer-Ingelheim, and Merck-Sharp and Dohme. Gilles Montale-scot has received research grants (institution) from ADIR, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Celladon, Daiichi-Sankyo, Eli-Lilly, ICAN, Fédération Française de Cardiologie, Medtronic, Merck-Sharp and Dohme, Pfizer, Sanofi-Aventis, and The Medicines Company and consultancy fees from Am-gen, AstraZeneca, Bayer, Berlin Chimie AG, Boehringer-Ingelheim, Bristol-Myers Squibb, Beth Israel Deaconess Medical, Brigham Women’s Hospital, Cardiovascular Research Foundation, CME Resources, Daiichi-Sankyo, Eli-Lilly, Europa, Elsevier, Fondazione Anna Maria Sechi per il Cuore, Gilead, Janssen, Lead-Up, Menarini, Merck-Sharp and Dohme, Pfizer, Sanofi-Aventis, The Medicines Company, TIMI Study Group, and WebMD. Muriel Licour and Anne Tsatsaris are employees of AstraZeneca, while Angel Cequier, Béla Merkely, Kurt Hu-ber, Olivier Stibbe, and Wim M.J.M. Heutz have nothing to disclose.
Publisher Copyright:
© 2018, Springer Nature Switzerland AG.
PY - 2019/4
Y1 - 2019/4
N2 - BackgroundMorphine adversely impacts the action of oral adenosine diphosphate (ADP)-receptor blockers in ST-segment elevation myocardial infarction (STEMI) patients, and is possibly associated with differing patient characteristics. This retrospective analysis investigated whether interaction between morphine use and pre-percutaneous coronary intervention (pre-PCI) ST-segment elevation resolution in STEMI patients in the ATLANTIC study was associated with differences in patient characteristics and management.MethodsATLANTIC was an international, multicenter, randomized study of treatment in the acute ambulance/hospital setting where STEMI patients received ticagrelor 180mgmorphine. Patient characteristics, cardiovascular history, risk factors, management, and outcomes were recorded.ResultsOpioids (97.6% morphine) were used in 921 out of 1862 patients (49.5%). There were no significant differences in age, sex or cardiovascular history, but more morphine-treated patients had anterior myocardial infarction and left-main disease. Time from chest pain to electrocardiogram and ticagrelor loading was shorter with morphine (both p=0.01) but not total ischemic time. Morphine-treated patients more frequently received glycoprotein IIb/IIIa inhibitors (p=0.002), thromboaspiration and stent implantation (both p
AB - BackgroundMorphine adversely impacts the action of oral adenosine diphosphate (ADP)-receptor blockers in ST-segment elevation myocardial infarction (STEMI) patients, and is possibly associated with differing patient characteristics. This retrospective analysis investigated whether interaction between morphine use and pre-percutaneous coronary intervention (pre-PCI) ST-segment elevation resolution in STEMI patients in the ATLANTIC study was associated with differences in patient characteristics and management.MethodsATLANTIC was an international, multicenter, randomized study of treatment in the acute ambulance/hospital setting where STEMI patients received ticagrelor 180mgmorphine. Patient characteristics, cardiovascular history, risk factors, management, and outcomes were recorded.ResultsOpioids (97.6% morphine) were used in 921 out of 1862 patients (49.5%). There were no significant differences in age, sex or cardiovascular history, but more morphine-treated patients had anterior myocardial infarction and left-main disease. Time from chest pain to electrocardiogram and ticagrelor loading was shorter with morphine (both p=0.01) but not total ischemic time. Morphine-treated patients more frequently received glycoprotein IIb/IIIa inhibitors (p=0.002), thromboaspiration and stent implantation (both p
KW - DOUBLE-BLIND
KW - ASSOCIATION
KW - REPERFUSION
KW - PRASUGREL
KW - OUTCOMES
KW - INSIGHTS
KW - TRIAL
U2 - 10.1007/s40256-018-0305-0
DO - 10.1007/s40256-018-0305-0
M3 - Article
C2 - 30353444
SN - 1175-3277
VL - 19
SP - 173
EP - 183
JO - American Journal of Cardiovascular Drugs
JF - American Journal of Cardiovascular Drugs
IS - 2
ER -